Procter & Gamble Hygiene & Healthcare Ltd.

NSE: PGHH | BSE: 500459

Expensive Performer

Download real time

13254.00 -162.00 (-1.21%)

25.31% Fall from 52W High

6,513 NSE+BSE Volume

NSE 10 Jul, 2025 1:25 PM (IST)

43,023.4

Market Cap

Above industry Median

0.3

Beta 1Year

Very Low volatility

Procter & Gamble Hygiene & Healthcare Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PGHH, BSE:500459 Procter & Gamble Hygiene & Healthcare Ltd.

Procter & Gamble Hygiene & Healthcare Ltd.

22 Aug 2019

13254.00

-1.21%

Sales momentum intact, but a big miss on margins

Neutral: Procter & Gamble Hygiene &...

Target

Motilal Oswal

22 August 2019 the fourth straight quarter of extremely healthy sales growth. Even adjusted for the GST effect on sanitary napkins (which optically inflates sales but has an adverse effect on operating costs), comparable growth stands healthy at 12% YoY for 4QFY19 and 14% YoY for FY19. EBITDA, however, was down 210bp YoY (off an extremely high base of 4QFY18), but other expenses were up by 330bp YoY. The sharp increase in other expenses (for which no explanations were provided) is surprising, given that it too has come off a very high base (+630bp YoY in 4QFY18). Net sales were up by 20% to INR29.5b. EBITDA declined 3% to INR6.1b, while adj. Margins have remained volatile over the past few years, but sales growth has revived significantly due to distribution expansion and sharp ad spends in the preceding quarters. While the structural growth opportunity in the feminine hygiene segment (~70% of sales) remains very promising, valuations of 52.

Number of FII/FPI investors increased from 137 to 150 in Mar 2025 qtr.

Procter & Gamble Hygiene & Healthcare Ltd.

08 May 2019

13254.00

-1.21%

Sales growth momentum sustains; margins below expectations

Neutral: Procter & Gamble Hygiene &...

Target

Motilal Oswal

3QFY19 (June-ending) net sales witnessed third consecutive quarter of strong sales revival at 22.9% YoY to INR7b (v/s est. of INR6.5b). EBITDA was in line at INR1.44b (down 1.9% YoY) and PAT was slightly below expectations at INR903m (v/s est. of INR928m), up 8.3% YoY. Management mentioned that adjusted for GST impact in the base quarter, sales growth was ~15%. Gross margins contracted 630bp YoY to 57.7%, likely due to (a) impact of 10% price cuts taken in Whisper Choice Ultra, and (b) absence of input tax credit under GST for sanitary napkins. Adspend declined off a high base by 270bp YoY...

Procter & Gamble Hygiene & Healthcare Ltd. is trading below all available SMAs

Procter & Gamble Hygiene & Healthcare Ltd.

07 Feb 2019

13254.00

-1.21%

Sales momentum sustains; material cut in EPS forecasts on major margin miss

Economy Update: Procter & Gamble Hygiene &...

Motilal Oswal

7 February 2019 which can be attributed to a combination of factors, such as (a) high commodity inflation levels, as also witnessed by peers so far in the Dec18 results, (b) 10% price cuts in and (c) absence of input tax credit under GST for sanitary napkins. EBITDA margin shrank 650bp YoY to 23.4%, led by higher ad spends (+140bp YoY fourth straight quarter of sharp increase YoY), employee cost (+40bp YoY) and other expenses (+10bp YoY). Net sales were up by 18.2% YoY to INR16.1b, EBITDA rose 0.8% YoY to INR4b and PAT grew 5.0% YoY to INR2.6b. Absence of input tax credit and price reduction will have an impact on margins in the subsequent quarters as category growth potential in the feminine hygiene segment (~70% of sales) and potential for market share growth because of its considerable moats and (2) potentially huge margin gains from premiumization over the longer term in feminine hygiene.

Number of FII/FPI investors increased from 137 to 150 in Mar 2025 qtr.

Procter & Gamble Hygiene & Healthcare Ltd.

08 Jan 2019

13254.00

-1.21%

Signs of revival after a couple of muted years

Neutral: Procter & Gamble Hygiene &...

Target

Motilal Oswal

8 January 2019 The aggression demonstrated by the PGHH management in recent quarters on increase in ad spends, new launches and price cuts, wherever required. Continued market share gain in Vicks. New product - Vicks Baby Rub, launched in FY18 is reportedly doing very well. While valuations of 51.7x FY20 EPS implies that near-term upside is limited, category growth potential in the Feminine Hygiene segment (~67% of sales) and potential for market share growth because of its considerable moats, and (2) Potentially huge margin gains from premiumization in Feminine Hygiene over the longer term. Increasing pace of distribution expansion, continuing strong pace of category development efforts in schools to boost awareness and growth, rising ad spends after a lull in preceding years, healthy pipeline of new products and willingness to take price cuts whenever required to boost growth are all encouraging developments that should aid rapid growth for the company over the long term.

Procter & Gamble Hyg.. has an average target of 15000.00 from 1 broker.

Procter & Gamble Hygiene & Healthcare Ltd.

03 Nov 2018

13254.00

-1.21%

Procter & Gamble Hygiene and Health Care Ltd Q2FY19 results Comment

Results Update: Procter & Gamble Hygiene &...

HDFC Securities

Procter & Gamble Hygiene and Health Care Ltd Q2FY19 results Comment Revenue rose by 50.92% to Rs. 791.8 Cr in Q1JY19 when compared to the previous quarter. Also, it rose by 20.41% when compared with Q1JY18.

Procter & Gamble Hygiene & Healthcare Ltd. is trading below all available SMAs

Procter & Gamble Hygiene & Healthcare Ltd.

30 Jun 2018

13254.00

-1.21%

Procter & Gamble Hygiene & Health Care Ltd.

Buy: Procter & Gamble Hygiene &...

Ashika Research

Number of MF schemes decreased from 21 to 15 in Mar 2025 qtr

Procter & Gamble Hygiene & Healthcare Ltd.

14 May 2018

13254.00

-1.21%

Procter & Gamble Hygiene and Health Care Ltd Q3JY18 results Comment

Results Update: Procter & Gamble Hygiene &...

HDFC Securities

Revenue fell by 19.21% to Rs. 568.89 Cr in Q3JY18 when compared to the previous quarter. Procter & Gamble Hygiene and Health Care Ltd Q3JY18 results Comment

Number of MF schemes decreased from 21 to 15 in Mar 2025 qtr

Procter & Gamble Hygiene & Healthcare Ltd.

05 Feb 2018

13254.00

-1.21%

P&G; Hygiene and Healthcare : Growth disappoints, given weak base; balance sheet metrics improving

Neutral: Procter & Gamble Hygiene &...

Recommendation Target

Motilal Oswal

2QFY18 net sales grew 9.5% YoY (against our estimate of 19% YoY) to INR7.0b. EBITDA declined 8% YoY (against our estimate of 6% YoY growth) to INR2.1b. Adjusted PAT declined 12.9% YoY (against our estimate of flat PAT) to INR1.3b. Management called out strong performance in both Feminine Hygiene and Healthcare, but sales were expected to be higher on weak base. Since gross and EBITDA margins for base quarter 2QFY17 were unusually high; we were expecting 380bp EBITDA margin decline. Operating margin decline was steeper than expected at 570bp YoY to 29.9%. Gross margin declined 350bp YoY to 60.1%. Encouragingly, ad spend to sales grew by 110bp YoY and by 24% YoY in absolute terms. This expense has been lower than expected in recent quarters. Other expenses increased 120bp YoY to 16.6%. Other income declined sharply due to massive dividend payout in May 2017

Procter & Gamble Hygiene & Healthcare Ltd. is trading below all available SMAs

Is Procter & Gamble Hygiene & Healthcare Ltd. worth buying?

107 Votes:

Buy 73.83%

Sell 14.95%

Hold 11.21%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf